Despite various public health strategies, malaria caused by Plasmodium falciparum
parasites remains a major global health challenge that requires development of new …

Malaria, caused by infection with Plasmodium parasites, drives multiple regulatory
responses across the immune landscape. These regulatory responses help to protect …

A vaccine targeting multiple stages of the Plasmodium falciparum parasite life cycle is
desirable. The sporozoite surface Circumsporozoite Protein (CSP) is the target of leading …

The development of an effective and durable vaccine remains a central goal in the fight
against malaria. Circumsporozoite protein (CSP) is the major surface protein of sporozoites …

Human monoclonal antibodies (mAbs) against the central repeat and junction domain of
Plasmodium falciparum circumsporozoite protein (PfCSP) have been studied extensively to …

The circumsporozoite protein (CSP) is the main surface antigen of the Plasmodium
sporozoite (SPZ) and forms the basis of the currently only licensed anti‐malarial vaccine …

The ability of the human immune system to generate antibodies to any given antigen can be
strongly influenced by immunoglobulin V-gene allelic polymorphisms. However, previous …

The proteome of Plasmodium falciparum (Pf) is abundant in intrinsically disordered proteins
(IDPs). Their important roles in the malaria life cycle and the limitations of experimental and …

Introduction Pre-erythrocytic malaria vaccines hold the promise of inducing sterile protection
thereby preventing the morbidity and mortality associated with Plasmodium infection. The …

Malaria remains a huge burden on global public health. Annually there are more than 200
million cases with> 600,000 deaths worldwide, the vast majority of which occur within Sub …